Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES)

Assistance Publique - Hôpitaux de Paris238 enrolled

Overview

Patients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

238

Conditions

Covid19 Neurologic Manifestations Psychiatric Manifestations

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

1. Age over 18 yo 2. Patient having presented or presenting a Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period 3. And patient with: 1. a neurological or psychiatric manifestation de novo during or after the Covid-19 infection and/or 2. either a chronic neurological or psychiatric pathology

Outcomes

Primary Outcomes

dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients

Time frame: 12 months

Secondary Outcomes

Serum neurofilaments

Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection